Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7740500 | 0.84 | KMT2A (0.46) | SLC6A4SLC6A3SLC6A2MEN1KMT2A | |
| SCHEMBL6947370 | 0.79 | SLC6A4 (0.73) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL6954904 | 0.77 | SLC6A4 (0.66) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL7221513 | 0.74 | BRD4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| Uk-390957 SCHEMBL931652 | 0.72 | SLC6A4 (1.00) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL6947732 | 0.71 | SLC6A4 (0.69) | SLC6A4SLC6A3SOS1SLC6A2KMT2A | |
| SCHEMBL6947359 | 0.71 | SLC6A4 (0.69) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL6151447 | 0.71 | SLC6A4 (1.00) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL7737267 | 0.71 | SLC6A4 (0.75) | SLC6A4SLC6A3SOS1SLC6A2 | |
| SCHEMBL930692 | 0.69 | SLC6A4 (1.00) | SLC6A4SLC6A3SOS1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | SLC6A4 34/4885SLC6A3 226/4885SOS1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.